{"2411.15215": {"publish_time": "2024-11-20", "title": "S$^2$ALM: Sequence-Structure Pre-trained Large Language Model for Comprehensive Antibody Representation Learning", "paper_summary": "Antibodies safeguard our health through their precise and potent binding to\nspecific antigens, demonstrating promising therapeutic efficacy in the\ntreatment of numerous diseases, including COVID-19. Recent advancements in\nbiomedical language models have shown the great potential to interpret complex\nbiological structures and functions. However, existing antibody specific models\nhave a notable limitation that they lack explicit consideration for antibody\nstructural information, despite the fact that both 1D sequence and 3D structure\ncarry unique and complementary insights into antibody behavior and\nfunctionality. This paper proposes Sequence-Structure multi-level pre-trained\nAntibody Language Model (S$^2$ALM), combining holistic sequential and\nstructural information in one unified, generic antibody foundation model. We\nconstruct a hierarchical pre-training paradigm incorporated with two customized\nmulti-level training objectives to facilitate the modeling of comprehensive\nantibody representations. S$^2$ALM's representation space uncovers inherent\nfunctional binding mechanisms, biological evolution properties and structural\ninteraction patterns. Pre-trained over 75 million sequences and 11.7 million\nstructures, S$^2$ALM can be adopted for diverse downstream tasks: accurately\npredicting antigen-antibody binding affinities, precisely distinguishing B cell\nmaturation stages, identifying antibody crucial binding positions, and\nspecifically designing novel coronavirus-binding antibodies. Remarkably,\nS$^2$ALM outperforms well-established and renowned baselines and sets new\nstate-of-the-art performance across extensive antibody specific understanding\nand generation tasks. S$^2$ALM's ability to model comprehensive and generalized\nrepresentations further positions its potential to advance real-world\ntherapeutic antibody development, potentially addressing unmet academic,\nindustrial, and clinical needs.", "paper_summary_zh": "<paragraph>\u6297\u9ad4\u900f\u904e\u7cbe\u6e96\u4e14\u5f37\u800c\u6709\u529b\u7684\u7d50\u5408\uff0c\u91dd\u5c0d\u7279\u5b9a\u6297\u539f\u4f86\u4fdd\u8b77\u6211\u5011\u7684\u5065\u5eb7\uff0c\u5728\u5305\u62ec COVID-19 \u5728\u5167\u7684\u8a31\u591a\u75be\u75c5\u7684\u6cbb\u7642\u4e2d\uff0c\u5c55\u73fe\u51fa\u6709\u5e0c\u671b\u7684\u6cbb\u7642\u529f\u6548\u3002\u751f\u7269\u91ab\u5b78\u8a9e\u8a00\u6a21\u578b\u7684\u6700\u65b0\u9032\u5c55\uff0c\u5df2\u986f\u793a\u51fa\u8a6e\u91cb\u8907\u96dc\u751f\u7269\u7d50\u69cb\u548c\u529f\u80fd\u7684\u5de8\u5927\u6f5b\u529b\u3002\u7136\u800c\uff0c\u73fe\u6709\u7684\u6297\u9ad4\u7279\u5b9a\u6a21\u578b\u6709\u4e00\u500b\u986f\u8457\u7684\u9650\u5236\uff0c\u5c31\u662f\u5b83\u5011\u7f3a\u4e4f\u5c0d\u6297\u9ad4\u7d50\u69cb\u8cc7\u8a0a\u7684\u660e\u78ba\u8003\u91cf\uff0c\u5118\u7ba1 1D \u5e8f\u5217\u548c 3D \u7d50\u69cb\u90fd\u80fd\u63d0\u4f9b\u7368\u7279\u4e14\u4e92\u88dc\u7684\u898b\u89e3\uff0c\u6df1\u5165\u4e86\u89e3\u6297\u9ad4\u884c\u70ba\u548c\u529f\u80fd\u3002\u672c\u6587\u63d0\u51fa\u5e8f\u5217\u7d50\u69cb\u591a\u5c64\u7d1a\u9810\u8a13\u7df4\u6297\u9ad4\u8a9e\u8a00\u6a21\u578b (S$^2$ALM)\uff0c\u5c07\u6574\u9ad4\u5e8f\u5217\u548c\u7d50\u69cb\u8cc7\u8a0a\u7d50\u5408\u5728\u4e00\u500b\u7d71\u4e00\u7684\u901a\u7528\u6297\u9ad4\u57fa\u790e\u6a21\u578b\u4e2d\u3002\u6211\u5011\u5efa\u69cb\u4e86\u4e00\u500b\u5206\u5c64\u9810\u8a13\u7df4\u7bc4\u4f8b\uff0c\u4e26\u7d50\u5408\u5169\u500b\u5ba2\u88fd\u5316\u591a\u5c64\u7d1a\u8a13\u7df4\u76ee\u6a19\uff0c\u4ee5\u5229\u65bc\u5efa\u6a21\u5168\u9762\u7684\u6297\u9ad4\u8868\u793a\u3002S$^2$ALM \u7684\u8868\u793a\u7a7a\u9593\u63ed\u793a\u4e86\u5167\u5728\u7684\u529f\u80fd\u7d50\u5408\u6a5f\u5236\u3001\u751f\u7269\u6f14\u5316\u7279\u6027\u548c\u7d50\u69cb\u4e92\u52d5\u6a21\u5f0f\u3002S$^2$ALM \u9810\u5148\u8a13\u7df4\u8d85\u904e 7500 \u842c\u500b\u5e8f\u5217\u548c 1170 \u842c\u500b\u7d50\u69cb\uff0c\u53ef\u63a1\u7528\u65bc\u5404\u7a2e\u4e0b\u6e38\u4efb\u52d9\uff1a\u6e96\u78ba\u9810\u6e2c\u6297\u539f\u6297\u9ad4\u7d50\u5408\u89aa\u548c\u529b\u3001\u7cbe\u78ba\u5340\u5206 B \u7d30\u80de\u6210\u719f\u968e\u6bb5\u3001\u8b58\u5225\u6297\u9ad4\u95dc\u9375\u7d50\u5408\u4f4d\u7f6e\uff0c\u4ee5\u53ca\u7279\u5225\u8a2d\u8a08\u65b0\u578b\u51a0\u72c0\u75c5\u6bd2\u7d50\u5408\u6297\u9ad4\u3002\u503c\u5f97\u6ce8\u610f\u7684\u662f\uff0cS$^2$ALM \u512a\u65bc\u65e2\u6709\u4e14\u77e5\u540d\u7684\u57fa\u7dda\uff0c\u4e26\u5728\u5ee3\u6cdb\u7684\u6297\u9ad4\u7279\u5b9a\u7406\u89e3\u548c\u751f\u6210\u4efb\u52d9\u4e2d\uff0c\u6a39\u7acb\u65b0\u7684\u6700\u5148\u9032\u6548\u80fd\u3002S$^2$ALM \u5efa\u6a21\u5168\u9762\u4e14\u5ee3\u6cdb\u8868\u793a\u7684\u80fd\u529b\uff0c\u9032\u4e00\u6b65\u5960\u5b9a\u4e86\u5176\u5728\u63a8\u9032\u73fe\u5be6\u4e16\u754c\u6cbb\u7642\u6027\u6297\u9ad4\u958b\u767c\u7684\u6f5b\u529b\uff0c\u6709\u53ef\u80fd\u6eff\u8db3\u672a\u6eff\u8db3\u7684\u5b78\u8853\u3001\u7522\u696d\u548c\u81e8\u5e8a\u9700\u6c42\u3002</paragraph>", "author": "Mingze Yin et.al.", "authors": "Mingze Yin, Hanjing Zhou, Jialu Wu, Yiheng Zhu, Yuxuan Zhan, Zitai Kong, Hongxia Xu, Chang-Yu Hsieh, Jintai Chen, Tingjun Hou, Jian Wu", "id": "2411.15215v1", "paper_url": "http://arxiv.org/abs/2411.15215v1", "repo": "null"}}